EP0694038A1 - Neuartige androgene und anabolika - Google Patents
Neuartige androgene und anabolikaInfo
- Publication number
- EP0694038A1 EP0694038A1 EP94910353A EP94910353A EP0694038A1 EP 0694038 A1 EP0694038 A1 EP 0694038A1 EP 94910353 A EP94910353 A EP 94910353A EP 94910353 A EP94910353 A EP 94910353A EP 0694038 A1 EP0694038 A1 EP 0694038A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound according
- androgen
- treatment
- treating
- substituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0025—Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Definitions
- the "complex androgen deficiency" of the man leads to an existential disorder, as a result of which, indefinitely, preferably from the age of 45 years onwards, with flowing symptom transitions, signs of male hormone deficiency can occur. These preferably consist of mood swings combined with the feeling of overwhelming psychosomatic performance. These disorders are often accompanied by an increasing impotentia coeundi, in which Consequences of depression and loss of self-esteem often occur; intellectual vigilance can also be restricted. Spermatogenesis is less affected. The weakening of the anabolic effectiveness of androgens, often in conjunction with a lack of training, leads to increasing atrophy of the muscles. This also reduces bone mass in the sense of osteoporosis. Blood formation can also be reduced.
- Maturitas 1: 305-317, 1989 is no longer approved in Germany by the Federal Health Office because of the insufficient effectiveness and possible side effects.
- HDL cholesterol high-density lipoproteins
- Exogenous supply of androgens and anabolic steroids causes the following changes in the lipid or lipoprotein blood concentrations: Decrease in triglycerides due to alteration of VLDL secretion or metabolism, Decrease in HDL, especially HDL2, effects on apoprotein A1 Synthesis with decrease in lipoprotein values and finally increase in LDL cholesterol concentrations (Crook D, Seed M Baillieres Clin.Endocrinol.Metab. 4: 851-875, 1990; Gillmer MD Int. J. Fert. 37: Suppl. 2 , 83-92, 1992; Alen M et al. Int. J. Sports Med. 6: 139-144, 1985; Christ DM et al. Clin. Exptl.
- LDL cholesterol low-density lipoproteins
- the invention is therefore based on the object of providing androgens or anabolics which show the above-described negative effects at least only to a greatly reduced extent, in order to treat them for various diseases without the above-described unfavorable effects on the development or exacerbation of one To make arteriosclerosis suitable.
- this object is achieved by the provision of novel types of androgens or anabolic steroids, which are distinguished by at least one substituent or one substituent grouping which shows the radical scavenger properties. While maintaining the basic androgenic / anabolic direction of action, an unexpectedly high inhibitory effect on lipid peroxidation is achieved. This special spectrum of effects is completely unexpected and atypical for
- substituents and substituent groups are: substituted or unsubstituted phenols; substituted or unsubstituted aromatic amines, sulfides, disulfides and thiols; Croman-6-ols, especially ⁇ -tocopherol and Trolox, including their derivatives and esters; Ascorbic acid, including its esters; 2,4-dipyrrolidino-6-N-piperidinopyrimidine, including their N'-alkyl and N'-acyl derivatives; Cysteine;
- Fixing solution 10% formaldehyde, 10% glacial acetic acid and 80% methanol.
- the fixed brains were removed and embedded in paraffin. Histological sections (5 ⁇ m thick and 1.4 to 3.0 ml behind the bregma) were placed on glass slides and stained with cresyl violet. Unchanged neurons stain with cresyl violet and can be counted with a 320x microscopic magnification. The direct comparison between the normal and ischemic hemisphere was always carried out.
- a protective function against neuron degeneration by carotid occlusion was found in a range from 0.5 to 50 mg / kg body weight.
- the androgens and anabolic agents according to the invention can be used above all for relieving depressive conditions and for the prophylaxis and therapy of osteoporosis with and without a combination with estrogen and / or gestagens, without having to accept an increase in the cardiovascular risk.
- Compounds based on testosterone can be used especially used for the treatment of benign prostate hypertrophy and prostate cancer.
- free oxygen radicals inter alia, in the context of vascular disorders or ischemically induced cerebral edema, subarachnoid hemorrhages, ischemic shock, cerebral insult, certain forms of asthma, Alzheimer's disease, Parkinson's disease, organ transplantation and play an essential atiopathogenetic role in androgen- or non-androgen-dependent malignancies.
- the compounds according to the invention also have therapeutic potential in these areas.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4312034 | 1993-04-13 | ||
DE4312034A DE4312034A1 (de) | 1993-04-13 | 1993-04-13 | Neuartige Androgene und Anabolika |
PCT/DE1994/000316 WO1994024146A1 (de) | 1993-04-13 | 1994-03-18 | Neuartige androgene und anabolika |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0694038A1 true EP0694038A1 (de) | 1996-01-31 |
Family
ID=6485366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94910353A Withdrawn EP0694038A1 (de) | 1993-04-13 | 1994-03-18 | Neuartige androgene und anabolika |
Country Status (6)
Country | Link |
---|---|
US (1) | US5795883A (de) |
EP (1) | EP0694038A1 (de) |
JP (1) | JPH08508506A (de) |
AU (1) | AU6281994A (de) |
DE (1) | DE4312034A1 (de) |
WO (1) | WO1994024146A1 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4338316A1 (de) * | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
US6376477B2 (en) | 1996-11-25 | 2002-04-23 | Merck & Co., Inc. | Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism |
EP1032397A1 (de) * | 1997-11-24 | 2000-09-06 | University Of Florida Research Foundation, Inc. | Testosterone inhibitoren und verwendung zum neuronalschutz |
DE19825591A1 (de) * | 1998-06-09 | 1999-12-23 | Jenapharm Gmbh | Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata |
HUP0200871A3 (en) * | 1999-05-04 | 2004-04-28 | Strakan Int Ltd | Androgen glycosides and androgenic activity thereof |
AU2002257430A1 (en) * | 2001-05-01 | 2002-11-11 | Mcgill University | Androgen-mediated neuroprotection and uses thereof |
WO2007048034A2 (en) * | 2005-10-21 | 2007-04-26 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Use of androgens for the treatment of parkinson' s disease |
US20090285893A1 (en) * | 2008-05-19 | 2009-11-19 | The Procter & Gamble Company | Treatment of heart failure in women |
KR101169850B1 (ko) | 2008-12-30 | 2012-07-30 | 서울대학교산학협력단 | 트로락스를 포함하는 골 대사성 질환 또는 골 전이성 암 질환 예방 및 치료용 약제학적 조성물 |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
WO2018098501A1 (en) | 2016-11-28 | 2018-05-31 | Lipocine Inc. | Oral testosterone undecanoate therapy |
CN111415745A (zh) * | 2020-04-03 | 2020-07-14 | 河北医科大学 | 一种雄激素提示老年男性阿尔茨海默病风险的计算方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2247390A1 (de) * | 1972-09-27 | 1974-03-28 | Merck Patent Gmbh | Neue 1-alkylthio-androstan-derivate |
WO1987001706A2 (en) * | 1985-09-12 | 1987-03-26 | The Upjohn Company | C20 through c26 amino steroids |
WO1987007895A1 (en) * | 1986-06-23 | 1987-12-30 | The Upjohn Company | Androstane-type and cortical aminoesters |
FR2644787B1 (fr) * | 1989-03-22 | 1995-02-03 | Roussel Uclaf | Nouveaux steroides 21 aminosubstitues, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant |
US5202316A (en) * | 1989-03-22 | 1993-04-13 | Roussel Uclaf | N,N,N',N'-6-(1-piperazinyl)-2,5-pyridinediamines |
JP2835066B2 (ja) * | 1989-03-24 | 1998-12-14 | 財団法人応用生化学研究所 | 生体内過酸化脂質増量抑制剤 |
DE3929913A1 (de) * | 1989-09-08 | 1991-04-04 | Hoechst Ag | 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte |
DE4000397A1 (de) * | 1990-01-09 | 1991-07-11 | Hoechst Ag | Lipidselektive antioxidantien sowie deren herstellung und verwendung |
-
1993
- 1993-04-13 DE DE4312034A patent/DE4312034A1/de not_active Withdrawn
-
1994
- 1994-03-18 WO PCT/DE1994/000316 patent/WO1994024146A1/de not_active Application Discontinuation
- 1994-03-18 AU AU62819/94A patent/AU6281994A/en not_active Abandoned
- 1994-03-18 JP JP6522600A patent/JPH08508506A/ja active Pending
- 1994-03-18 EP EP94910353A patent/EP0694038A1/de not_active Withdrawn
- 1994-03-18 US US08/537,725 patent/US5795883A/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of WO9424146A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1994024146A1 (de) | 1994-10-27 |
AU6281994A (en) | 1994-11-08 |
DE4312034A1 (de) | 1994-10-20 |
US5795883A (en) | 1998-08-18 |
JPH08508506A (ja) | 1996-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994024146A1 (de) | Neuartige androgene und anabolika | |
DE69627831T2 (de) | Benzopyran-enthaltende verbindungen und verfahren zu deren verwendung | |
DE69731473T2 (de) | Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen | |
DE2532000A1 (de) | Aliphatische carbonsaeureester von vitamin e und verfahren zu ihrer herstellung | |
DE10206390A1 (de) | Verwendung von selektiv den Estrogenrezeptor beta modulierenden phytoestrogenhaltigen Extrakten | |
DE69720996T2 (de) | Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer | |
EP0986573B1 (de) | Nichtestrogene derivate des estradiols mit antioxidativer aktivität | |
DE3430799A1 (de) | Verfahren zur behandlung von osteoporose | |
DE3490215C2 (de) | ||
Klempien et al. | Der umsatz von dehydroisoandrosteron in der hundeleber | |
EP1747229A1 (de) | Steroid-prodrugs mit androgener wirkung | |
EP0753300B1 (de) | Verwendung von Steroiden mit antioxidativen Eigenschaften zur Herstellung von pharmazeutischen Präparaten zur medikamentösen Substitution beim Mann | |
DE2610497C2 (de) | In 16-Stellung disubstituierte 3- Ketosteroide, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DE60311779T2 (de) | Steroidale Chinole als Prodrugs von Antioxidantien | |
DE3336292C2 (de) | ||
Wilhelm et al. | Biological activity assessment of the 26, 23-lactones of 1, 25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 and their binding properties to chick intestinal receptor and plasma vitamin D binding protein | |
EP1064002A1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
SEGALOFF et al. | The role of adrenal steroids and ACTH in gluconeogenesis | |
Ahmed et al. | EFFECTS OF CASTRATION AND SEX HORMONES ON ANTIOXIDANT STATUS AND SOME BIOCHEMICAL PARAMETERS OF MALE RABBITS EXPOSED TO OXIDATIVE STRESS | |
Kar et al. | The effect of testosterone propionate on total cholesterol content of the testis in young rats | |
EP0442350A1 (de) | Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung | |
DE10251028A1 (de) | Verwendung von Progesteron oder einem Progesteronrezeptor-Agonisten zur Hemmung der Steroidsynthese | |
DE1667958C (de) | Beständige ölige Lösungen von therapeutisch wirksamen Steroid-Enol-Äthern | |
EP0031591A1 (de) | 2,2-Dimethyl-3-oxoandrosta-4,6-dien-17S-spiro-5'-(2'-oxo-3'-methyloxazolidin), Verfahren zu seiner Herstellung und dieses enthaltende Arzneimittel | |
DE2323615A1 (de) | Zootechnische zusammensetzungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19951108 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19960916 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: JENAPHARM GMBH & CO. KG |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 20010222 |